Alternatives
A Cortellis alternative — for companies without a CI team.
Cortellis and Prognyx are not the same kind of product, and the choice is not about which is better. It is about whether you are buying data or buying analysis.
People search for a Cortellis alternative for one of three reasons: the annual subscription is out of proportion to a single-asset company's budget, nobody internally has time to work inside the platform, or the need is narrower than an all-of-pharma dataset. Occasionally all three.
Prognyx is an alternative for the second and third of those, and a partial answer to the first. It is not a cheaper Cortellis — it is a different shape of purchase, and that distinction is the whole decision.
What Cortellis actually is
Cortellis is Clarivate's pharmaceutical intelligence platform: a large body of structured data spanning drug pipelines, clinical trials, regulatory intelligence, patents, deals and competitive landscape modules, accessible through a search-and-analytics interface and licensed as an enterprise subscription.
It is genuinely strong at what it is built for. The breadth is real, the data is normalised so it can be queried and exported, and for an analyst who needs to answer arbitrary questions across all of pharma it is a serious tool. Nothing on this page disputes that.
What Prognyx is
Prognyx is not a platform. It is an outsourced oncology competitive-intelligence function: one analyst who watches your competitive set continuously and sends you briefs on what changed, what it means for your asset and what to do about it — every claim traced to the primary record.
| Dimension | Cortellis | Prognyx |
|---|---|---|
| What you buy | A software subscription — access to structured pharma intelligence data | A person’s output — the watch, the analysis and the recommendation |
| Who does the analysis | Your team, inside the platform | Prognyx, before it reaches you |
| Therapeutic coverage | All of pharma, across drugs, trials, patents, regulatory and deals | Oncology only, deliberately |
| Delivery | A login. You go to it | A brief. It comes to you |
| Best case | A trained analyst with time and a research question | A CBO or CMO with a competitor readout and no analyst |
| Seats | Priced and provisioned per seat | Not applicable — the deliverable is forwardable |
| Contract shape | Typically annual, enterprise procurement | Month to month, written scope, no lock-in |
| Onboarding | Training to use the platform effectively | A 30-minute scoping conversation |
| Accountability for a wrong read | The read is yours — the platform supplied data | One named analyst, publicly |
| Published pricing | Not published | Published — from $2,000/mo |
When Cortellis is the better buy
Straightforwardly, and without hedging:
- You have analysts. If you employ people whose job is competitive intelligence, they need a data environment to work in, and Prognyx does not provide one. Buy the platform.
- You need coverage beyond oncology. Prognyx covers oncology only and will decline the rest rather than cover it thinly.
- You need patents, IP landscapes or chemistry data. Not Prognyx's scope at all.
- You need to export structured data into your own models, dashboards or valuation work. A brief is prose; a platform gives you rows.
- You need to answer arbitrary ad-hoc questions across the whole industry at volume. That is what a queryable dataset is for.
When Prognyx is the better buy
- The work currently happens at 11pm. If competitive intelligence is a task on your CBO's or CMO's evening rather than someone's job, a platform adds a login to an already-full week. The bottleneck is analyst hours, not data access.
- Your competitive set is narrow and deep. One or two assets, a defined mechanism, a handful of rivals with dates attached. All-of-pharma breadth is capacity you would pay for and not use.
- You need the "so what", not the "what". The hard part of a rival's hazard ratio landing without a p-value is not finding it; it is knowing what it does to your filing strategy.
- The budget is real. Enterprise CI subscriptions are structured for organisations with a CI department to amortise them. Prognyx publishes its floor: from $2,000/mo, scoped to your pipeline.
- You want someone accountable. A platform supplies data; if the read is wrong, the read was yours. Here it is Rali Filali's, by name.
The cost question, honestly
Clarivate does not publish Cortellis pricing, and this page will not invent a number for it. What can be said structurally: enterprise pharma intelligence subscriptions are priced per seat and per module, on annual terms, through a procurement process — a shape designed for organisations that will use them broadly.
The more useful comparison for a small company is not licence versus retainer. It is total cost including the senior hours needed to turn data into a decision. A subscription nobody has time to mine has a real cost and delivers nothing; that is the failure mode Prognyx exists to remove.
Using both
These are not mutually exclusive, and pretending otherwise would be dishonest. Companies that already hold a platform subscription sometimes bring in Prognyx for depth on one asset ahead of a specific decision — a readout, a licensing conversation, a board cycle — while the platform continues to serve broad questions. Nothing about Prognyx requires you to cancel anything.
How to decide in one question
Ask who will read the data. If the answer is a named person whose job is competitive intelligence, buy the platform. If the answer is "we'll find someone", buy the analysis — because "we'll find someone" is how a subscription becomes shelfware and a competitor's readout becomes a surprise.
Comparison last reviewed 25 July 2026. This page describes Cortellis from its public product information and does not claim to be exhaustive; Cortellis does not publish list pricing, and nothing here invents any. Prognyx has no affiliation with Cortellis. Verify current scope and pricing with the vendor directly before any purchase decision. Names and trademarks referenced belong to their owners.
Frequently asked
What is the best Cortellis alternative for a small biotech?
It depends on what is actually scarce. If you have analysts and need cheaper or narrower data, look at other platforms in the category (Citeline, Evaluate, GlobalData, AlphaSense). If what you lack is analyst time rather than data access, the alternative is a delivered service rather than another subscription — which is what Prognyx is: continuous oncology competitive intelligence from $2,000/mo, with the analysis already done.
Is Prognyx cheaper than Cortellis?
Cortellis pricing is not public, so no honest direct comparison is possible and this page will not fabricate one. Prognyx publishes its own floor — $2,000/mo — which is deliberately positioned for companies with one lead asset and no CI department. The two are also not substitutes: one sells data access, the other sells finished analysis.
Can Prognyx replace a Cortellis subscription?
For a company whose competitive intelligence need is oncology-only, narrow and decision-driven — often yes, because what it needed was never the dataset. For a company with staffed analysts, broad therapeutic coverage needs, or patent and chemistry requirements, no. Those are real capabilities Prognyx does not have.
Does Prognyx use Cortellis data?
No. Prognyx works from primary public records — ClinicalTrials.gov, FDA and EMA actions, SEC filings, peer-reviewed literature and congress abstracts — and cites each one directly so you can open it yourself. See how we work.
Compare the output, not the brochures.
Name one asset you'd want watched. You get a real competitive brief on it — free, sourced, no obligation. Then judge.
Request a sample brief → See a sample first